Abstract: A traction improvement device provides increased traction to a tracked vehicle. The traction improvement device has two opposing brackets that are connected to opposite edges or flanges of a track of a tracked vehicle. A chain extends between the brackets. At least one of the brackets is a tensioner bracket that is configured to adjust the tension of the chain. The tension adjustment provides tension to the chain extending between the brackets, securing the traction improvement device on the outer surface (or gripping surface) of the track.

Abstract: A traction improvement device provides increased traction to a tracked vehicle. The traction improvement device has two opposing brackets that are connected to opposite edges or flanges of a track of a tracked vehicle. A chain extends between the brackets. At least one of the brackets is a tensioner bracket that is configured to adjust the tension of the chain. The tension adjustment provides tension to the chain extending between the brackets, securing the traction improvement device on the outer surface (or gripping surface) of the track.

Abstract: The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.

Abstract: A mechanism for securing a series of fiber optic cable connectors includes a base that has several connector recesses and a lid that is removably attached to the base. The mechanism may be used to ruggedly connect a series of fiber optic cables in a downhole instrument where space is limited, with the ability to break each of the series of fiber optic cables individually.

Abstract: A mechanism for securing a series of fibre optic cable connectors includes a base that has several connector recesses and a lid that is removably attached to the base. The mechanism may be used to ruggedly connect a series of fibre optic cables in a downhole instrument where space is limited, with the ability to break each of the series of fibre optic cables individually.

Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.

Abstract: The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUCl-1 or derivative thereof. The invention further provides pharmaceutical compositions comprising said constructs and proteins, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine, particularly in the treatment of MUCl-1 expressing tumours.

Abstract: The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumors. In particular, the nucleic acid is DNA and the DNA constructs comprise a gene encoding a MUC-1 derivative having less than 10 perfect repeat units. The invention further provides pharmaceutical compositions comprising said constructs, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine. Novel proteins encoded by the nucleic acid and pharmaceutical compositions containing them are also provided.

Abstract: The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines comprising polynucleotide sequences encoding HCV proteins, and methods of treatment of individuals infected with HCV comprising administration of the vaccines of the present invention.

Abstract: Novel MUC-1 DNA constructs are provided that have reduced homology to native MUC-1. Pharmaceutical compositions containing such MUC-1 constructs are provided.

Abstract: The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.

Abstract: The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for prostate tumours in humans, to immunogenic compositions containing them, to methods of manufacture of such compositions and to their use in medicine. Methods for formulating vaccines for immunotherapeutically treating P501S-expressing prostate tumors, prostatic hyperplasia, and prostate intraepithelilial neoplasia (PIN) are also provided.

Abstract: The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines that encode the HCV Core protein and a polynucleotide sequence that encodes at least one other HCV protein, wherein the vaccine causes expression of the proteins within the same cell and the sequence of the polynucleotide sequence encoding the core protein has been mutated or positioned relative to the polynucleotide sequence encoding the at least one other HCV protein such that the negative effect of expression of the Core protein upon the expression of the said at least one other HCV protein is reduced.

Abstract: The present invention provides nucleic acid constructs useful in nucleic acid vaccination for the treatment and prophylaxis of Muc-1 expressing tumours. The constructs are devoid of Muc-1 perfect repeats.

Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.